Advertisement
Corrigendum
Open Access |
10.1172/JCI204857
Find articles by Schackmann, R. in: PubMed | Google Scholar
Find articles by van Amersfoort, M. in: PubMed | Google Scholar
Find articles by Haarhuis, J. in: PubMed | Google Scholar
Find articles by Vlug, E. in: PubMed | Google Scholar
Find articles by Halim, V. in: PubMed | Google Scholar
Find articles by Roodhart, J. in: PubMed | Google Scholar
Find articles by Vermaat, J. in: PubMed | Google Scholar
Find articles by Voest, E. in: PubMed | Google Scholar
Find articles by van der Groep, P. in: PubMed | Google Scholar
Find articles by van Diest, P. in: PubMed | Google Scholar
Find articles by
Jonkers, J.
in:
PubMed
|
Google Scholar
|
Find articles by Derksen, P. in: PubMed | Google Scholar
Published March 2, 2026 - More info
Metastatic breast cancer is the major cause of cancer-related death among women in the Western world. Invasive carcinoma cells are able to counteract apoptotic signals in the absence of anchorage, enabling cell survival during invasion and dissemination. Although loss of E-cadherin is a cardinal event in the development and progression of invasive lobular carcinoma (ILC), little is known about the underlying mechanisms that govern these processes. Using a mouse model of human ILC, we show here that cytosolic p120-catenin (p120) regulates tumor growth upon loss of E-cadherin through the induction of anoikis resistance. p120 conferred anchorage independence by indirect activation of Rho/Rock signaling through interaction and inhibition of myosin phosphatase Rho–interacting protein (Mrip), an antagonist of Rho/Rock function. Consistent with these data, primary human ILC samples expressed hallmarks of active Rock signaling, and Rock controlled the anoikis resistance of human ILC cells. Thus, we have linked loss of E-cadherin — an initiating event in ILC development — to Rho/Rock-mediated control of anchorage-independent survival. Because activation of Rho and Rock are strongly linked to cancer progression and are susceptible to pharmacological inhibition, these insights may have clinical implications for the development of tailor-made intervention strategies to better treat invasive and metastatic lobular breast cancer.
Ron C.J. Schackmann, Miranda van Amersfoort, Judith H.I. Haarhuis, Eva J. Vlug, Vincentius A. Halim, Jeanine M.L. Roodhart, Joost S. Vermaat, Emile E. Voest, Petra van der Groep, Paul J. van Diest, Jos Jonkers, Patrick W.B. Derksen
Original citation: J Clin Invest. 2011;121(8):3176–3188. https://doi.org/10.1172/JCI41695
Citation for this corrigendum: J Clin Invest. 2026;136(5):e204857. https://doi.org/10.1172/JCI204857
In Figure 1A of the original article, the H&E-stained images for the Wcre;Trp53fl/fl and Human ILC samples as well as the E-cadherin-stained images for the K14cre;Cdh1fl/fl;Trp53fl/fl and Human ILC samples were incorrect and were inadvertently duplicated from a prior publication in Cancer Cell (1). In addition, the H&E-stained image for the K14cre;Cdh1fl/fl;Trp53fl/fl sample and all of the p120-stained images have been replaced. The corrected figure panel, based on the original source material and data, is provided below.
The authors regret the errors.